You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Biodesix, which raised about $63 million in a recent initial public offering, said it ended 2020 with roughly $62 million in cash and cash equivalents.
For the three months ended Sept. 30, the Boulder, Colorado-based firm generated a revenue of $9.2 million, compared to $3.9 million year over year.
William Blair, Canaccord Genuity, and BTIG on Monday initiated coverage of newly public Biodesix, with ratings ranging from Buy to Outperform.
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
Quidel's preliminary earnings more than doubled over the prior quarter on increasing SARS-CoV-2 test sales.
The firm is using ddPCR to support testing 3,000 samples per day with a turnaround time of approximately 24 hours
The companies are working together to secure US Food and Drug Administration Emergency Use Authorization for the digital droplet PCR test.
The diagnostic firm has agreed with Streck to incorporate its blood collection tubes into sample collection protocols for its genomic lung cancer tests.
The firms will use Biodesix's biomarker discovery platform to analyze the proteome of pancreatic cancer patients treated with Immodulon's immunotherapy IMM-101.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.